(HealthDay News) — Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial offers surprising results on the best second-line drug to use in these cases. The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the […]